{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:28:53Z","timestamp":1795127333442,"version":"4.10.3"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate associations between use of seven progestogens and incident acute venous thromboembolism (VTE) among women of reproductive age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      This nested matched case\u2013control study identified women aged 15\u201349 years from January 1, 2010, through October 8, 2018, in the IBM MarketScan databases, a nationwide sample of private insurance claims in the United States. After exclusions, 21,405 women with incident acute VTE (case group), identified by diagnosis codes, were matched 1:5 by year of birth and index date through risk set sampling to 107,025 women without prior VTE (control group). From lowest to highest systemic dose based on a modified hierarchy, progestogens studied were levonorgestrel-releasing intrauterine device (LNG-IUD), oral norethindrone, etonogestrel implant, oral progesterone, oral medroxyprogesterone acetate, oral norethindrone acetate, and depot medroxyprogesterone acetate (DMPA). Conditional logistic regression models adjusted for 16 VTE risk factors were used to estimate odds ratios and 99% CIs for incident acute VTE associated with current progestogen use compared with nonuse. The primary analysis treated each progestogen as a binary exposure. Dose, which varied for oral formulations, and chronicity were explored separately. Significance was set at\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.01 to allow for multiple comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Current use of higher-dose progestogens was significantly associated with increased odds of VTE compared with nonuse (oral norethindrone acetate: adjusted odds ratio [aOR] 3.00, 99% CI 1.96\u20134.59; DMPA: aOR 2.37, 99% CI 1.95\u20132.88; and oral medroxyprogesterone acetate: aOR 1.98, 99% CI 1.41\u20132.80). Current use of other progestogens was not significantly different from nonuse (LNG-IUD, etonogestrel implant, and oral progesterone) or had reduced odds of VTE (oral norethindrone). Sensitivity analyses that assessed misclassification bias supported the primary findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Among reproductive-aged women using one of seven progestogens, only use of norethindrone acetate and medroxyprogesterone acetate\u2014considered higher-dose progestogens\u2014was significantly associated with increased odds of incident acute VTE. The roles of progestogen type, dose, and indication for use warrant further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004896","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T17:00:46Z","timestamp":1659632446000},"page":"477-487","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":56,"title":["Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age"],"prefix":"10.1097","volume":"140","author":[{"given":"Richard H.","family":"Cockrum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari G.","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R2-20260916","first-page":"1","article-title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R3-20260916","first-page":"1","article-title":"FSRH guideline (January 2019) combined hormonal contraception (revision due by January 2024) [published erratum appears in BMJ Sex Reprod Health 2021;47:e2]","volume":"45","year":"2019","journal-title":"BMJ Sex Reprod Health"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2016.04.014","article-title":"Progestin-only contraception and thromboembolism: a systematic review","volume":"94","author":"Tepper","year":"2016","journal-title":"Contraception"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis","volume":"345","author":"Mantha","year":"2012","journal-title":"BMJ"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/2047487318774847","article-title":"Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis","volume":"25","author":"Glisic","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/AOG.0000000000003135","article-title":"Venous thromboembolism among women initiating depot medroxyprogesterone acetate immediately postpartum","volume":"133","author":"Tepper","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/AOG.0000000000003760","article-title":"Association of immediate postpartum etonogestrel implant insertion and venous thromboembolism","volume":"135","author":"Floyd","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-0528.2008.01926.x","article-title":"The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case\u2013control study using the General Practice Research Database","volume":"116","author":"Sundstr\u00f6m","year":"2009","journal-title":"BJOG"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/dc16-1534","article-title":"Hormonal contraception and risk of thromboembolism in women with diabetes","volume":"40","author":"O'Brien","year":"2017","journal-title":"Diabetes Care"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/00016340902730375","article-title":"Limited knowledge on progestogen-only contraception and risk of venous thromboembolism","volume":"88","author":"Bergendal","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/AOG.0000000000000411","article-title":"Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes","volume":"124","author":"Bergendal","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/ATVBAHA.110.211482","article-title":"The risk of deep venous thrombosis associated with injectable depot\u2013medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device","volume":"30","author":"van Hylckama Vlieg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.thromres.2010.08.010","article-title":"Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study","volume":"126","author":"Barsoum","year":"2010","journal-title":"Thromb Res"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)03132-3","article-title":"Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications","volume":"354","author":"Poulter","year":"1999","journal-title":"Lancet"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)04394-9","article-title":"Risk of idiopathic venous thromboembolism in users of progestagens alone","volume":"354","author":"Vasilakis","year":"1999","journal-title":"Lancet"},{"key":"R19-20260916","first-page":"e128","article-title":"Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206 [published erratum appears in Obstet Gynecol 2019;133:1288]. American College of Obstetricians and Gynecologists","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajog.2015.07.044","article-title":"The medical management of abnormal uterine bleeding in reproductive-aged women","volume":"214","author":"Bradley","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/AOG.0000000000002518","article-title":"Abnormal vaginal bleeding in women desiring contraception who are taking anticoagulation therapy","volume":"131","author":"Bonnington","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1055\/s-0040-1715793","article-title":"Hormonal contraceptives and the risk of venous thrombosis","volume":"46","author":"Khialani","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jfprhc-2012-100345","article-title":"Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism","volume":"38","author":"Mansour","year":"2012","journal-title":"J Fam Plann Reprod Health Care"},{"key":"R24-20260916","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmjsrh-2020-200619","article-title":"Norethisterone and its acetate \u2013 what's so special about them?","volume":"47","author":"Huvinen","year":"2021","journal-title":"BMJ Sex Reprod Health"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0010-7824(01)00309-2","article-title":"Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use","volume":"65","author":"Heinemann","year":"2002","journal-title":"Contraception"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MLR.0000000000000524","article-title":"Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study","volume":"55","author":"Fang","year":"2017","journal-title":"Med Care"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"e004499","DOI":"10.1136\/bmjopen-2013-004499","article-title":"Exposure to combined oral contraceptives and risk of venous thromboembolism: a protocol for nested case\u2013control studies using the QResearch and the CPRD databases","volume":"4","author":"Vinogradova","year":"2014","journal-title":"BMJ Open"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.thromres.2015.10.022","article-title":"Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome","volume":"136","author":"Okoroh","year":"2015","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"R33-20260916","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.maturitas.2003.09.016","article-title":"Differential effects of progestins on hemostasis","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/13625189909064007","article-title":"Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women","volume":"4","author":"Heinemann","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.contraception.2011.04.009","article-title":"Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide","volume":"84","author":"Endrikat","year":"2011","journal-title":"Contraception"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestins","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.thromres.2012.05.024","article-title":"Risk factors for venous thromboembolism in pre- and postmenopausal women","volume":"130","author":"Bergendal","year":"2012","journal-title":"Thromb Res"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.320.7233.503","article-title":"Expressing the magnitude of adverse effects in case-control studies: \u201cthe number of patients needed to be treated for one additional patient to be harmed\u201d","volume":"320","author":"Bjerre","year":"2000","journal-title":"BMJ"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/pds.4197","article-title":"Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism","volume":"26","author":"Renoux","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.thromres.2012.02.042","article-title":"Progestin-only contraception and venous thromboembolism","volume":"129","author":"Blanco-Molina","year":"2012","journal-title":"Thromb Res"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jog.13306","article-title":"Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users","volume":"43","author":"Melhado\u2010Kimura","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/humrep\/dem153","article-title":"Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade","volume":"22","author":"Vieira","year":"2007","journal-title":"Hum Reprod"},{"key":"R46-20260916","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/jc.2007-0044","article-title":"Formation of ethinyl estradiol in women during treatment with norethindrone acetate","volume":"92","author":"Chu","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R47-20260916","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jcph.1079","article-title":"In vivo formation of ethinylestradiol after intramuscular administration of norethisterone enantate.","volume":"58","author":"Friedrich","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"R48-20260916","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0010-7824(97)00174-1","article-title":"In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women","volume":"56","author":"Kuhnz","year":"1997","journal-title":"Contraception"},{"key":"R49-20260916","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/hc4801.099737","article-title":"Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor","volume":"104","author":"Herkert","year":"2001","journal-title":"Circulation"},{"key":"R50-20260916","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"R51-20260916","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cgh.2014.07.017","article-title":"Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease","volume":"13","author":"Higgins","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R52-20260916","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2005.07.001","article-title":"Synthetic progestins used in HRT have different glucocorticoid agonist properties","volume":"242","author":"Koubovec","year":"2005","journal-title":"Mol Cel Endocrinol"},{"key":"R53-20260916","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.contraception.2014.02.006","article-title":"Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs","volume":"90","author":"Huijbregts","year":"2014","journal-title":"Contraception"},{"key":"R54-20260916","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0010-7824(98)00041-9","article-title":"Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study","volume":"57","year":"1998","journal-title":"Contraception"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:40Z","timestamp":1789556620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004896","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"2022-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}